Sky Investment Group LLC Purchases 942 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Sky Investment Group LLC boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.5% in the 4th quarter, HoldingsChannel reports. The firm owned 18,072 shares of the medical research company’s stock after acquiring an additional 942 shares during the period. Thermo Fisher Scientific makes up about 1.7% of Sky Investment Group LLC’s portfolio, making the stock its 16th largest position. Sky Investment Group LLC’s holdings in Thermo Fisher Scientific were worth $9,402,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Mountain Pacific Investment Advisers LLC increased its holdings in shares of Thermo Fisher Scientific by 2.0% during the 4th quarter. Mountain Pacific Investment Advisers LLC now owns 42,611 shares of the medical research company’s stock worth $22,168,000 after acquiring an additional 853 shares during the last quarter. Gemmer Asset Management LLC increased its holdings in shares of Thermo Fisher Scientific by 8.7% in the fourth quarter. Gemmer Asset Management LLC now owns 464 shares of the medical research company’s stock valued at $241,000 after purchasing an additional 37 shares during the last quarter. LaFleur & Godfrey LLC raised its position in shares of Thermo Fisher Scientific by 9.1% in the fourth quarter. LaFleur & Godfrey LLC now owns 29,767 shares of the medical research company’s stock valued at $15,486,000 after purchasing an additional 2,488 shares during the period. Mitchell Mcleod Pugh & Williams Inc. lifted its stake in shares of Thermo Fisher Scientific by 3.1% during the 4th quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 1,669 shares of the medical research company’s stock worth $868,000 after buying an additional 50 shares during the last quarter. Finally, Zhang Financial LLC grew its stake in Thermo Fisher Scientific by 13.9% in the 4th quarter. Zhang Financial LLC now owns 426 shares of the medical research company’s stock valued at $222,000 after buying an additional 52 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the transaction, the executive vice president now directly owns 16,663 shares of the company’s stock, valued at $9,333,946.08. The trade was a 1.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $554.29, for a total value of $5,542,900.00. Following the completion of the sale, the chief executive officer now owns 121,192 shares in the company, valued at $67,175,513.68. The trade was a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 47,150 shares of company stock worth $25,954,465 in the last quarter. 0.34% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on TMO. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective for the company in a report on Friday, January 10th. Stifel Nicolaus reduced their price target on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. Redburn Atlantic assumed coverage on Thermo Fisher Scientific in a research report on Monday, October 14th. They set a “buy” rating and a $680.00 price objective on the stock. Robert W. Baird reduced their target price on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Finally, Scotiabank started coverage on shares of Thermo Fisher Scientific in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $605.00 price objective for the company. Four analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $648.95.

Thermo Fisher Scientific Stock Down 0.4 %

TMO stock opened at $559.72 on Tuesday. The stock has a market capitalization of $214.09 billion, a P/E ratio of 35.09, a price-to-earnings-growth ratio of 3.71 and a beta of 0.76. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The firm has a 50-day moving average price of $529.96 and a 200-day moving average price of $568.56. Thermo Fisher Scientific Inc. has a 12 month low of $493.30 and a 12 month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The firm had revenue of $10.60 billion for the quarter, compared to analysts’ expectations of $10.63 billion. During the same quarter in the previous year, the firm posted $5.69 earnings per share. The company’s revenue was up .2% on a year-over-year basis. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its board has approved a share buyback plan on Friday, November 15th that permits the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th were issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. The ex-dividend date was Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.78%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.